×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HALO – halozyme therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HALO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/11
06:32 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
2/10
04:33 pm
halo
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results [Yahoo! Finance]
Low
Report
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results [Yahoo! Finance]
2/10
04:05 pm
halo
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
Low
Report
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
2/10
11:26 am
halo
Biotech: Halozyme CEO explains what it looks for in M&A targets [Yahoo! Finance]
Low
Report
Biotech: Halozyme CEO explains what it looks for in M&A targets [Yahoo! Finance]
2/10
11:16 am
halo
Biotech: Halozyme CEO explains what it looks for in M&A targets [Yahoo! Finance Canada]
Low
Report
Biotech: Halozyme CEO explains what it looks for in M&A targets [Yahoo! Finance Canada]
2/6
10:36 am
halo
A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance [Yahoo! Finance]
Low
Report
A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance [Yahoo! Finance]
2/3
12:01 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
2/2
11:45 pm
halo
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth [Seeking Alpha]
Low
Report
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
11/3/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
2.8%
halozyme therapeutics, inc.
8/5/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
2.4%
halozyme therapeutics, inc.
5/6/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
18.1%
halozyme therapeutics, inc.
2/18/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
-0.2%
halozyme therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/11
09:22 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Feb 09 Filed by: Caudill Cortney
Medium
Report
Form 4 HALOZYME THERAPEUTICS, For: Feb 09 Filed by: Caudill Cortney
2/11
09:21 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Feb 09 Filed by: Snyder Mark Howard
Medium
Report
Form 4 HALOZYME THERAPEUTICS, For: Feb 09 Filed by: Snyder Mark Howard
2/11
09:21 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Feb 09 Filed by: LaBrosse Nicole
Medium
Report
Form 4 HALOZYME THERAPEUTICS, For: Feb 09 Filed by: LaBrosse Nicole
2/11
08:56 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Feb 09 Filed by: Torley Helen
Medium
Report
Form 4 HALOZYME THERAPEUTICS, For: Feb 09 Filed by: Torley Helen
2/5
07:39 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Feb 03 Filed by: Torley Helen
Medium
Report
Form 4 HALOZYME THERAPEUTICS, For: Feb 03 Filed by: Torley Helen
2/3
04:17 pm
halo
Form 144 HALOZYME THERAPEUTICS, Filed by: Torley Helen
Low
Report
Form 144 HALOZYME THERAPEUTICS, Filed by: Torley Helen
1/28
06:40 am
halo
Form 8-K HALOZYME THERAPEUTICS, For: Jan 28
Medium
Report
Form 8-K HALOZYME THERAPEUTICS, For: Jan 28
1/6
06:57 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Jan 02 Filed by: Lang James Paul
Low
Report
Form 4 HALOZYME THERAPEUTICS, For: Jan 02 Filed by: Lang James Paul
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/12
Form 8-K/A HALOZYME THERAPEUTICS, For: Oct 30
21.4%
11/5 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $16.00 price target on the stock, down previously from $17.00. 10.6%
5/1 FDA OKs subcutaneous version of J&J's Darzalex [Seeking Alpha] 8.1%
3/20 Form DEFA14A HALOZYME THERAPEUTICS, 8.0%
1/9 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. 8.0%
4/3 Form 4 HALOZYME THERAPEUTICS, For: Apr 01 Filed by: Sun Elaine D 6.2%
1/14 Halozyme Provides 2020 Business Update And Financial Guidance 5.9%
1/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. 5.4%
3/19 Form 4 HALOZYME THERAPEUTICS, For: Mar 19 Filed by: Kelley Kenneth J 4.5%
11/13 Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 4.5%
11/5 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $16.00 price target on the stock, down previously from $17.00. 10.6%
5/1 FDA OKs subcutaneous version of J&J's Darzalex [Seeking Alpha] 8.1%
3/20 Form DEFA14A HALOZYME THERAPEUTICS, 8.0%
1/9 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. 8.0%
4/3 Form 4 HALOZYME THERAPEUTICS, For: Apr 01 Filed by: Sun Elaine D 6.2%
1/14 Halozyme Provides 2020 Business Update And Financial Guidance 5.9%
1/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. 5.4%
3/19 Form 4 HALOZYME THERAPEUTICS, For: Mar 19 Filed by: Kelley Kenneth J 4.5%
11/13 Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 4.5%
TOP News Decliners
2/27
argenx SE (ARGX) Q4 2019 Earnings Call Transcript [The Motley Fool]
-4.5%
4/3 Halozyme Announces Change Of Location Of Annual Stockholders' Meeting -4.4%
2/26 Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference -4.3%
5/13 Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 -4.2%
8/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -3.9%
8/6 Halozyme Reports Second Quarter 2019 Results -3.2%
9/4 Form 8-K HALOZYME THERAPEUTICS, For: Sep 04 -3.2%
2/25 Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at JPMorgan Chase & Co. from $24.00 to $22.00. They now have an "overweight" rating on the stock. -3.0%
7/19 Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology -3.0%
7/3 Form SC 13D/A HALOZYME THERAPEUTICS Filed by: KIRK RANDAL J -2.0%
4/3 Halozyme Announces Change Of Location Of Annual Stockholders' Meeting -4.4%
2/26 Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference -4.3%
5/13 Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 -4.2%
8/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -3.9%
8/6 Halozyme Reports Second Quarter 2019 Results -3.2%
9/4 Form 8-K HALOZYME THERAPEUTICS, For: Sep 04 -3.2%
2/25 Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at JPMorgan Chase & Co. from $24.00 to $22.00. They now have an "overweight" rating on the stock. -3.0%
7/19 Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology -3.0%
7/3 Form SC 13D/A HALOZYME THERAPEUTICS Filed by: KIRK RANDAL J -2.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: